Kornimate/medical-research-clean huggingface dataset:
impact of a dedicated geriatric sector on the loss of functional autonomy at 1 month for patients admitted to emergencies and non-hospitalised

Conditions: Health Services for the Aged; Emergency Service, Hospital; Ambulatory Care

Summary: several studies have shown that going to the emergency room is a risk factor for loss of independence in the elderly. it has been shown that the period following an emergency room visit without hospitalization is a period of vulnerability for the elderly. the functional decline, or loss of functional autonomy, of the elderly is associated with an increase in institutionalization, mortality and costs to society. studies have highlighted the risk factors for functional decline in the elderly, such as pre-existing functional and cognitive decline, undernutrition, but no model of care has yet prevented the risk of loss of autonomy after a stay in the emergency room. a full and early geriatric assessment could prevent functional decline after the emergency room visit. the primary objective of the study is to assess the impact of a dedicated geriatric sector on the functional decline at 1 month of patients admitted to emergencies without hospitalization by comparing an intervention group (patient having benefited from the geriatric sector) and a group witness ("classic" emergency patient). the secondary objective is to evaluate the impact of this sector on the number of falls at home as well as the readmission rate within 1 month of going to the emergency room.


Eligibility criteria:
inclusion criteria: * age greater than or equal to 75 years * emergency room consultation between 7:30 a.m. and 5:30 p.m. * relevant to the adult emergency department * return home after consultation exclusion criteria: * age less than 75 years * arrival time between 5.30 p.m. and 7.30 a.m. * need to take care of unhooking * belonging to the short sector, versatile sector * patients hospitalized after consultation

Keywords: elderly geriatric sector autonomy
the effect of the physiotherapy program applied in the neonatal intensive care unit

Conditions: Premature; Infant, Light-for-dates; Neonatal Disease; Neurodevelopmental Disorders; Motor Delay

Summary: the aim of our study is to examine the effects of the physiotherapy program applied in the nicu on motor performance, behavior, transition time to full enteral feeding, and feeding performance in preterm infants.

preterm babies have to stay in neonatal intensive care units (nicu) because they cannot complete intrauterine development and have difficulty maintaining their vital functions. in very low birth weight babies, feeding may not be started at the desired time due to medical problems. total parenteral nutrition should be started in order to prevent growth retardation in the baby who cannot receive adequate enteral nutrition in the first days. the infant who tolerates enteral feeding should also be transitioned to full enteral feeding as soon as possible. early enteral nutrition and intensive early parenteral nutrition reduce growth retardation and improve the infant's mental developmental scores. the frequent occurrence of feeding intolerance in preterm infants with very low birth weight, especially extremely low birth weight, and the risk of nec, which is a serious cause of mortality and morbidity in these infants, prevent reaching the desired nutritional goals. therefore, the optimum initiation time and rate of increase of enteral feeding are still uncertain for these infants. the main purpose of preterm nutrition should be to minimize the problems that may occur in the short and long term. the aim of our study is to examine the effects of the physiotherapy program applied in the nicu on motor performance, behavior, transition time to full enteral feeding and feeding performance in preterm infants.

Eligibility criteria:
inclusion criteria: * born 30 weeks or younger of gestational age, body weight below 1500 g, the baby's vital signs are stable. exclusion criteria: * infants undergo surgery, taking antibiotics or phototherapy, having a genetic syndrome • having other medical conditions that may affect physiotherapy practices, such as multiple congenital anomalies, tracheoesophageal fistula, diaphragmatic hernia, congenital heart malformation, and/or necrotizing enterocolitis, the baby is intubated.
the effect of natural food flavourings on gastrointestinal and cardiovascular physiological responses.

Conditions: Gastric Emptying; Diabetes Mellitus

Summary: the purpose of this study is to determine whether 3 g cinnamon was sufficient to delay the gastric emptying rate of a high-fat solid meal and subsequently reduce postprandial blood glucose and lipid responses, oxidative stress, arterial stiffness and satiety responses in a healthy adult population.

cinnamon has been shown to delay gastric emptying (ge) of a high-carbohydrate meal and reduce postprandial glycaemia in healthy adults. however, it is dietary fat which is implicated in the etiology and is associated with obesity, type 2 diabetes (t2d) and cardiovascular disease (cvd). we aimed to determine the effect of 3 g cinnamon on ge, postprandial lipemic and glycemic responses, oxidative stress, arterial stiffness, as well as appetite sensations and subsequent food intake following a high-fat (hf) meal. the effect of acute oral administration of 3 g cinnamon on gastric emptying of a high-fat pancake test meal and subjective appetite sensations by visual analogue scale will be measured for six hours postprandially. during this time course, measurements of postprandial lipemic, glycemic, oxidative stress and arterial stiffness responses will be collected. subsequently, food intake will be measured using an ad libitum buffet meal. the study will be conducted in a randomized, placebo-controlled, single-blinded manner in 9 healthy subjects.

Eligibility criteria:
inclusion criteria: * healthy adults aged 18-35 years * recreationally trained individuals (participate in at least 2hrs/wk of individual/team sport) * not currently taking antioxidant or lipid-lowering medication * fasting blood lipid, glucose and blood pressure (bp) levels were all within the normal limits. exclusion criteria: * history of gastrointestinal-related conditions, diabetes mellitus or cardiovascular disease. * allergies to foods in study. * blood disorder * pregnancy.

Keywords: antioxidants glucose intolerance prevention and control diabetes mellitus prevention and control
dairy foods compared to dietary supplements and bone health

Conditions: Osteoporosis; Bone Loss; Osteopenia

Summary: does the consumption of dairy foods reduce the rate of bone loss in older women more than calcium and vitamin d supplements.

research indicates that bone health is dependent on multiple nutrients, not just calcium and vitamin d, leading to the conclusion that calcium from sources that include other bone enhancing nutrients may be more effective in maintaining bone integrity than calcium and vitamin d supplements. several studies have examined the effects of calcium intake from dairy foods on different indicators of bone health. reducing the rate of bone loss in postmenopausal women can reduce the risk of osteoporosis related fractures. therefore we propose to study the effectiveness of 4 servings of milk and yogurt per day for 42 days compared to calcium and vitamin d supplements for 42 days to reduce calcium loss from the skeleton in post menopausal women. postmenopausal women, approximately 50-65 years of age, will be studied. each volunteer will receive both interventions in a cross-over design, in random order, separated by a 42 day washout period.

Eligibility criteria:
inclusion criteria: * minimum 24 months since last menses * no hormone therapy in the past 12 months * weight stable for the past 3 months * bone density t score -1.7 to 0.0 * no more than two dairy servings per day * no history of inflammatory disorders * no history of non-traumatic bone fracture * no supplement use or willing to discontinue * no lactose intolerance * willing to consume milk and yogurt exclusion criteria: * less than 24 months since last menses * use of hormone therapy in past yr * \> 5 pound weight change in past 3 months * osteoporosis * regular \>2 servings/d of dairy * auto-immune/inflammatory disorders * history of non-traumatic bone fracture * unwilling to discontinue supplements * lactose intolerance * unwilling to eat yogurt or drink milk
study of the safety and immunogenicity of an intranasal vaccine for respiratory syncytial virus in seropositive children

Conditions: Respiratory Syncytial Virus Infections

Summary: this study evaluates an investigational vaccine that is designed to protect humans against infection with respiratory syncytial virus (rsv) and is administered as drops in the nose. specifically, the study analyzes the safety of, and the immune response to, the vaccine when administered to healthy children between the ages of 15 and 59 months who are seropositive to rsv.


Eligibility criteria:
key inclusion criteria: 1. children aged 15-59 months 2. good health based on history, physical examination and medical record review, without evidence or suspicion of chronic disease 3. seropositive to rsv, as defined by serum neutralizing antibody titer above the threshold described in the study analytical plan 4. written informed consent provided by parent(s)/guardian(s) key exclusion criteria: 1. known or suspected chronic illness, particularly cardiopulmonary (including asthma or reactive airways disease), metabolic, hepatic, renal, or infectious (including recurrent or chronic sinusitis) 2. known or suspected immunodeficiency 3. household or close contact with anyone ≤ 6 months of age or with immunocompromised individual(s) 4. nasal obstruction (including due to anatomic/structural causes, acute or chronic rhinosinusitis, or other causes) 5. receipt of immunoglobulins, monoclonal antibodies and/or any blood products, or ribavirin within 3 months prior to study inoculation, or planned during study period 6. receipt of an investigational rsv vaccine at any time 7. any other condition that, in the judgment of the investigator, would be a risk to participant's safety and/or may interfere with study procedures or interpretation of results

Keywords: live attenuated vaccine safety immunogenicity phase 1 clinical trial pediatric seropositive
depolarising electrical skin stimulation in neuropathic and postoperative pain

Conditions: Neuropathy;Peripheral

Summary: the aim of the study is to evaluate voltage gated sodium channel (nav1.7) dependent pain phenomena in neuropathic pain and chronic postoperative pain.

sinus-like electrical stimulation may depolarize unmyelinated skin nociceptors involving nav1.7 channels. in this case electrical stimulation may provoke pain already with very low currency intensity which normally not provoke pain in healthy subjects. this may be predictive for pain relief due to the sodium channel blocker lidocaine 5% patch. the study will characterize pain states in peripheral neuropathic pain as well as within the painful scar in chronic postoperative pain with regard to the involvement of nav1.7 channels. in addition, the pain site in chronic postoperative pain (scar) will be characterized by laser-evoked potentials (lep) and quantitative sensory testing (qst). pain related questionnaires will be obtained.

Eligibility criteria:
inclusion criteria: * group (1) patients with neuropathic pain * group (2) patients with chronic postoperative pain exclusion criteria (both groups): * severe psychiatric disorder requiring hospitalisation in the past * any neurological disease other than the pain diagnosis

Keywords: neuropathic pain chronic postoperative pain
a study of pd1 combined with dc-nk cell in the treatment of solid tumors

Conditions: Solid Tumor

Summary: clinical study on the safety and efficacy of pd1 combined with dc-nk in the treatment of solid tumors


Eligibility criteria:
inclusion criteria: 1. previously receiving ≥ first-line regimen chemotherapy; 2. age over 3 years old and less than 14 years old; 3. the expected survival period is more than 3 months; 4. ecog≤2; 5. vital organ function is satisfied: cardiac ultrasound indicates cardiac ejection fraction ≥ 50%, no obvious abnormality in ecg; blood oxygen saturation ≥ 90%; creatinine clearance calculated by cockcroft-gault formula ≥ 40ml/min; alt and ast ≤ 3 times the normal range, total bilirubin ≤ 2.0 mg / dl; 6. blood routine: hgb≥80g/l, anc≥1×109/l, plt≥50×109/l; there are measurable target lesions. exclusion criteria: 1. liver and kidney function: * total bilirubin \> 2 x uln (gilbert syndrome \> 3 x uln) * aspartate aminotransferase (ast) and alanine aminotransferase (alt) \> 3 × uln * serum creatinine clearance \>60ml/min 2. serological examination: * absolute neutrophil count (anc) \<0.75x109/l * platelet count (plt) \<50x109/l 3. active hepatitis b (hbv-dna \> 1000 copies / ml), hepatitis c, or uncontrolled infection; 4. the number of days of chemotherapy medication and the administration of hormones below 5mg is ≤3, and the number of days of withdrawal of hormones greater than 5mg is ≤5; 5. active cns disease (tumor cells in csf); 6. intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation; 7. creatinine \> 1.5 times the upper limit of normal or alt / ast \> 3 times the upper limit of normal or bilirubin \> 2 times the upper limit of normal; 8. the new york heart association (nyha) is classified as level iii or higher; 9. uncontrolled diabetes; 10. with other uncontrolled diseases, the investigator believes that it is not suitable for joining; 11. any situation that the investigator believes may increase the risk of the subject or interfere with the test results.
serial measurements of biomarker in patients with acute decompensated heart failure

Conditions: Acute Heart Failure

Summary: evaluation of serial measurement of novel biomarker for diagnosis, prognosis or therapy monitoring in patients presenting with acute decompensated heart failure.

background: heart failure (hf) is a chronic and progressive illness resulting from a variety of cardiac causes, including ischemic and valvular heart disease, dilatative cardiomyopathy or hypertension. hf may also develop suddenly, particularly as a complication of acute myocardial infarction or as an acute exacerbation in patients with previously compensated chronic hf. diagnosis and in-hospital management of hf is often demanding and outcome especially regarding rehospitalizations is impaired. novel biomarker may be very helpful in assessment of diagnosis, prognosis, and severity of hf as well as for treatment monitoring. design: prospective, multicenter observational study setting: university hospital basel, kantonsspital aarau, kantonsspital luzern, kantonsspital wolhusen patients: patients with acute hf not requiring icu admission measurement of serial biomarker (bnp, nt-probnp, mr-proadm, st2, hs-ctni and copeptin) will be performed at presentation, at 6 hours (h), 12h, 18h, 24h, at 48h, at day 6 and at hospital discharge. follow- up will be performed at 6 month, 1 year and 2 years.

Eligibility criteria:
inclusion criteria: * acute hf * informed consent exclusion criteria: * cardiogenic shock, st-elevation myocardial infarction, or other clinical conditions that require immediate icu admission or urgent ptca
intense therapeutic ultrasound for the treatment of chronic plantar fasciitis

Conditions: Plantar Fasciitis, Chronic

Summary: a clinical trial evaluating the effectiveness, safety and patient tolerance for the use of intense therapeutic ultrasound (itu) for chronic, plantar fasciitis musculoskeletal tissue pain reduction began in august 2016 and was completed in april 2017. the clinical setting: university foot and ankle institute, santa monica, california, usa; single-blinded, pivotal study for chronic plantar fasciitis.

intense therapeutic ultrasound (itu) is an established ultrasound based therapy in which sound waves are concentrated and focused into selected musculoskeletal tissue, to produce selective thermal coagulative changes over a small controlled area while leaving the surrounding tissue unaffected. these coagulative changes are known to begin the body's tissue response cascade and promote collagen generation in the targeted anatomy resulting in pain reduction.

Eligibility criteria:
inclusion criteria: * chronic pain (\>90 days) from previously diagnosed plantar fasciitis, where "standard of care" regimens failed to relief pain in the affected anatomy. * no history of surgery to the affected anatomy. * no alternative treatment procedures within the last 90 days. * age: 18 - 85, depending on the study. * unilateral pain * willingness to complete treatment and post treatment regimen as described. * patients who have provided written and verbal informed consent. exclusion criteria: * patients currently enrolled in any other non-conservative, device, or investigational new drug clinical trial, or who have participated in a clinical study involving the plantar fascia, thirty days prior to study initiation; * patients who have participated in any other clinical study involving an investigational product 30 days prior to enrollment that, in the opinion of the principal investigator, could affect the outcome of this study; * patients who have received previous treatment in the symptomatic limb (not including conservative treatment); * at the principal investigator's discretion, any patient that should be excluded based on their current condition or medical history.
treatment of ssri-resistant depression in adolescents (tordia)

Conditions: Depression

Summary: the purpose of the study is to determine how best to treat adolescents with depression that is "resistant" to the first ssri antidepressant they have tried. participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy.

the tordia study aims to develop useful clinical guidelines for the care and management of adolescent depression. adolescents ages 12 to 18, currently taking a prescribed selective serotonin reuptake inhibitor (ssri) and still experiencing depression, participate in a 12-week randomized treatment study that includes one of four conditions: (1) switching to an alternative ssri, (2) switching to a different non-ssri antidepressant, (3) switching to an alternative ssri and receiving cognitive behavioral therapy (cbt), or (4) switching to a different non-ssri antidepressant and receiving cbt. this is a double-blind study, which means that neither the participant nor the clinical staff will know which of the three possible medications has been assigned. participants who respond to the assigned treatment will receive 12 additional weeks of the same treatment. those who do not appear to be getting better will be offered 12 weeks of an alternative, individualized treatment plan based on each participant's particular needs. all participants will receive follow-up psychiatric evaluations for 12 months after the 12-week continuation phase of the study, regardless of treatment adherence.

Eligibility criteria:
* between the ages of 12 and 18 years 11 months * currently in treatment for depression * taking prozac,zoloft, luvox, lexapro, celexa or paxil (oregon and rhode island sites only) * still feeling depressed

Keywords: depressive disorder adolescents teenagers teens cognitive behavior therapy
effects of maple syrup on gut microbiota diversity and metabolic syndrome

Conditions: Overweight; Microbiota; Endotoxemia; Metabolic Syndrome; Non-Alcoholic Fatty Liver Disease; Insulin Resistance

Summary: it has been suggested that the actual obesity epidemy is related to chronic overconsumption of added or free sugars. the increasing popularity of artificial sweeteners attest the population willingness to reduce added sugars intake and to use alternatives to alleviate health impact of free sugar overconsumption. however, recent findings suggest that artificial sweeteners may rather contribute to obesity epidemy and its associated adverse health effects, potentially via a negative impact on gut microbiota. it has been shown in various studies that, for the same amount of sucrose, unrefined sugars (such as maple syrup) are associated with favorable metabolic effects. the polyphenols contained in maple syrup, especially lignans, could contribute to these positive effects. indeed, the strong impact of those biomolecules on the modulation of gut microbiota and on gastro-intestinal and metabolic health has been demonstrated in several studies. it is therefore highly relevant to test the hypothesis that the substitution of refined sugar by an equivalent amount of maple syrup (5% of daily energy intake) result in a lesser metabolic deterioration, by the modulation of maple syrup on gut microbiota, than the one observed with refined sugar.


Eligibility criteria:
inclusion criteria: * bmi between 23 and 40 kg/m2 * at least one of the following: fasting triglyceride \> 1,35 mmol/l, fasting insulinemia \> 42 pmol/l, fasting glycemia between 5,5 and 6,9 mmol/l and glycated haemoglobin (hba1c) between 5.7 and 6.4 % * understanding of spoken and written french * accept to follow study instructions * if there is natural health product consumption, the dose and frequency of consumption must be stable since 3 months or more exclusion criteria: * smoking * any metabolic disorder requiring medication or affecting glucose or lipid metabolism * aversion for maple taste * allergy or intolerance for maple syrup or for an ingredient of the placebo syrup * alcohol consumption of \> 2 drinks / day * weight change \> 5% of body weight in the last 3 months * being in a weight loss attempt * antibiotics intake in the last 3 months * regular probiotics intake in the last 3 months * major surgical operation in the last 3 months or planned in the next months * gastrointestinal malabsorption * cirrhosis * chronic kidney disease * pregnant or breastfeeding women or women planning pregnancy in the next months * participation in another clinical trial